Postpartum Depression - Pipeline Insight, 2025

DelveInsight’s, “Postpartum Depression - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Postpartum Depression: Understanding

Postpartum Depression: Overview

Postpartum depression (PPD) is a serious health issue that can affect about 15% of the female population within after giving birth. It often conveys significant negative consequences to the offsprings. The symptoms and risk factors are somewhat similar to those found in non-postpartum depression. The main difference resides in the fact that PPD is triggered by postpartum specific factors, including especially biological changes in the hormone levels. Patients are usually diagnosed using a questionnaire onsite or in a clinic. Treatment of PPD often involves psychotherapy and antidepressant medications. The signs and symptoms of PPD are identical to non-puerperal depression with an additional history of childbirth. Symptoms include depressed mood, loss of interest, changes in sleep patterns, change in appetite, feelings of worthlessness, inability to concentrate, and suicidal ideation. Women may also experience anxiety. Patients having PPD may also have psychotic symptoms which include delusions and hallucinations (voices saying to harm infant).

The pathogenesis of postpartum depression is currently unknown. It has been suggested that genetics, hormonal and psychological, and social life stressors play a role in the development of PPD. The role of reproductive hormones in depressive behavior suggests neuroendocrine pathophysiology for PPD. The pathophysiology of PPD can be caused by alterations of multiple biological and endocrine systems, for example, the immunological system, the hypothalamic-pituitary-adrenal axis (HPA), and lactogenic hormones. The Hypothalamic-pituitary-adrenal axis (HPA) is known to be involved in the disease process of post-partum depression. HPA axis causes the release of cortisol in trauma and stress, and if the HPA axis function is not normal, then the response decreases the release of catecholamines leading to the poor stress response.

Postpartum depression is diagnosed when at least five depressive symptoms are present for at least 2 weeks. Screening for PPD can be done 2 to 6 months after childbirth. There are several screening tools available, and one of the most frequently used is the Edinburgh Postnatal Depression Scale (EPDS). It is a 10-item questionnaire filled out by patients and takes a few minutes to complete. An EPDS cutoff score equal to or greater than 13 is required to determine if patients are at risk for developing PPD. First-line treatment for peripartum depression is psychotherapy and antidepressant medications. Psychosocial and psychological psychotherapy is the first-line treatment option for women with mild to moderate peripartum depression. A combination of therapy and antidepressant drugs is recommended for women with moderate to severe depression.

""Postpartum Depression- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postpartum Depression pipeline landscape is provided which includes the disease overview and Postpartum Depression treatment guidelines. The assessment part of the report embraces, in depth Postpartum Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postpartum Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression R&D. The therapies under development are focused on novel approaches to treat/improve Postpartum Depression.

Postpartum Depression Emerging Drugs Chapters

This segment of the Postpartum Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postpartum Depression Emerging Drugs

RE-104: Reunion Neuroscience

RE104 is a proprietary, potential best-in-class, serotonergic neuroplastogen. RE-104 is designed as a single-dose psychedelic that offers a fast onset and shorter treatment duration, as well as reproducible pharmacokinetics. It has potential across a variety of neuropsychiatric indications, including in PPD and AjD, where Reunion is focusing its initial clinical development efforts. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Postpartum Depression.

GH001: GH Research

GH001 is an inhaled formulation of mebufotenin (5-MeO-DMT), a psychedelic compound that acts as a potent serotonin 5-HT1A and 5-HT2A receptor agonist. By rapidly modulating serotonergic signaling, GH001 is believed to induce profound and short-lasting psychoactive effects, which may help reset dysfunctional neural circuits implicated in mood disorders. It is being investigated for treatment-resistant depression (TRD), bipolar II disorder, and postpartum depression.

BRII-297: Brii Bio

BRII-297 is a first-of-its-kind long-acting injectable (LAI) therapeutic candidate in development for the treatment of various anxiety and depressive disorders. Discovered internally, BRII-297 acts as a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator (PAM), a proven mechanism of action that is known to potentially restore ""normal"" levels GABAA receptor function for various depressive and anxiety central nervous system disorders. Currently, the drug is in Phase I stage of its clinical trial for the treatment of postpartum depression.

Further product details are provided in the report……..

Postpartum Depression: Therapeutic Assessment

This segment of the report provides insights about the different Postpartum Depression drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postpartum Depression

There are approx. 10+ key companies which are developing the therapies for Postpartum Depression. The companies which have their Postpartum Depression drug candidates in the most advanced stage, i.e. Phase II include, Reunion Neuroscience.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postpartum Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Postpartum Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postpartum Depression drugs.

Postpartum Depression Report Insights

Postpartum Depression Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Postpartum Depression Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Postpartum Depression drugs?

How many Postpartum Depression drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postpartum Depression?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Postpartum Depression and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GH Research

Reunion Neuroscience

Lipocine

Brii Biosciences Limited

Key Products

GH001

RE-104

LPCN1154

BRII-297

Please Note: It will take 1-2 business days to complete the report upon order confirmation.